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     Chinese Hamster Ovary (CHO) cells are widely used in the industrial production of 
commercial therapeutics. One key aspect to the productivity of these cells is their high rate of 
glucose consumption. The high rate of glucose consumption is paired with a high output of 
lactate which can lead to negative culture performance. The rate of glucose consumption and 
lactate production can be modulated by a number of chemicals, some of which are being 
explored as therapeutic drugs, which affect the activities of the enzymes involved in glucose 
metabolism.  This research aimed to evaluate the effects caused by small molecule therapeutics 
on CHO cells’ metabolism using a mathematic model of glucose metabolism. To model the 
therapeutics, established kinetic information for these therapeutics was implemented into a 
metabolic model. Then different concentrations of therapeutics were explored to assess their 
effects on metabolism. In addition, combinations of therapeutics were examined to study the 
effects of more drastic changes to metabolism. These therapeutics showed a large impact to the 
bistability of glucose metabolism as well as the lactate flux. These outcomes were important due 
to the potential to increase the productivity of CHO cells for industrial use as well as decreasing 
cell death. Thus, these therapeutics could be used to reduce lactate production in cells allowing 





























     The Warburg effect is the phenomenon describing how cancer cells consume glucose at high 
rates while also outputting lactate at high rates [1].  The Warburg effect is commonly seen in cell 
culture due to their proliferative nature.  Chinese Hamster Ovary (CHO) cells are a cell line 
commonly used for industrial cell cultures to create products, particularly commercial 
therapeutic proteins [2].  These CHO cells, even when in environments with excess oxygen, can 
still display high glucose flux and high lactate flux.  The high lactate output can have negative 
implications on productivity, and cell viability [3].  In batch cultures these cells produce high 
amounts of lactate which can cause high osmolarity over time due to the necessity to add base to 
counteract the acidity caused by lactate.    
     This issue is not new, and different methods to address high lactate output have been used in 
the past.  One method which has shown success was the substitution of glucose for other sugars 
after the growth phase.  The sugars that were promising included galactose, fructose and 
mannose [4].  These sugars are useful due to their lower binding affinity to transporters, which 
causes slower uptake.  Modified feeding of these cells therefore proves to be a useful method in 
the controlling of lactate flux [5]. 
     While some genetic engineering in CHO cells has proven to be successful in the past, other 
changes have been detrimental.  An example of this is efforts made to knock out lactate 
dehydrogenenase (LDH), the enzyme responsible for the conversion of pyruvate to lactate.  It 
should be noted that these efforts have caused cell death indicating that likely knocking down 
LDH or other enzymes in glucose metabolism would prove to be more effective at lowering flux 
without causing cell death [6]. 
     When looking at the ways that glucose metabolism has been modified, small molecule 
therapeutics show up repeatedly in use for treatments.  In particular, small molecule therapeutics 
have been investigated for use in the treatment of many different cancers.  Cancer cells, like 
CHO cells are rapidly dividing, and also tend to be at a high flux state producing lactate.  
Therefore, small molecule therapeutics were selected to be used in smaller concentrations then 
when used in cancer treatment, as that was used to induce cell death. 
     The goal of this research was to model the behaviors of glucose metabolism in the presence of 
small molecule therapeutics.  The therapeutics chosen were inhibitors of LDH, glucose 
transporter 1 (GLUT1), pyruvate dehydrogenase kinase isoform 2 (PDK2), phosphofructokinase 
1 (PFK1), monocarboxylate transporter 1 (MCT1), 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase (PFKFB), hexokinase (HK) and an activator of pyruvate kinase muscle isozyme 2 
(PKM2).  These enzymes were chosen to be inhibited and activated due to their importance to 
glucose metabolism and as they were frequently targeted in gene expression experiments seeking 





2.1 Inhibitor and Activator Kinetics 
     To identify target enzymes for inhibition and activation, multiple past publications were 
studied. These targets included LDH, GLUT1, PKM2, PDK2, MCT1, PFK1, PFKFB, and 
PKM2. For majority of the inhibitors, Michaelis-Menten kinetics for competitive inhibition were 
used [7]. The exception to this was PDK2 inhibitor AZD7545 which could not be directly added 
into the model due to the fact that PDK2 is not explicitly a part of the model. PDK2 is excluded 
from the model because it performs a post translation protein modification which is beyond the 
scope of the model. Instead, the impact of inhibiting PDK2 was approximated by changing the 
activity of PDHC, which allows an impact on PDK2 without knowing precise concentrations 
needed for the observed effects. The only activator being considered was TEPP-46, and activator 
of PKM2. TEPP-46 was added into the model using a multiplier which is currently a part of the 
model that determines the activity level of PKM2. 
Enzyme Therapeutic Ki Mechanism Citation 
GLUT1 WZB117 6.2 μM Competitive [8] 
HK 2-Deoxglucose 0.3 mM Competitive [9] 
PFKFB YZ9 0.094 μM Competitive [10] 
LDHA FX11 8 μM Competitive [11] 
MCT1 AZD3965 1.6 nM Competitive [12] 
PDK2 AZD7545 IC50 = 87 μM Competitive [13] 
PFK-1 Palmitoyl-CoA 1 μM Competitive [14] 
PKM2 TEPP-46 0.1 nM Activator [15] 
 
 
2.2 Gathering Therapeutic Data 
     After all therapeutics were incorporated into the model, each one was tested individually over 
a range of concentrations within which metabolism was sensitive to changes using the MATLAB 
model and the Minnesota Supercomputing Institute. The concentrations over which the most 
drastic changes in behavior where focused on and tested in combination for a few inhibitors.  
Units used when measuring the amount of inhibitor added are in mM unless otherwise stated. 
 
 
2.3 Testing Conditions 
     All of the concentrations of inhibitor were tested at steady state using a kinetic metabolic 
model developed previously [16].  Steady state is used because the conditions that CHO cells are 
held in are kept close to steady state so it is a good approximation.  All inhibitors and activators 
were tested independently of each other except for in a select few tests seeking the effects of 
combinations.  In the simulations with changing inhibitor concentrations, the amount of lactate is 
 
 
held constant at 6mM so that bistability can be observed.  This concentration was also chosen as 
it is a reasonable concentration that occurs in CHO cell cultures.   
 
3. Results and Discussion 
3.1 Inhibitor and Activator Simulation 
     For each therapeutic selected concentrations were tested until the apparent maximum effect 
was achieved.  The graphs representing each individual run of the model are shown in Figure 1. 
In addition, the inhibitors impact over a range of inhibitor concentrations with a constant lactate 
concentration are also shown. 
     The first inhibitor shown in Figure 1 is WZB117, a competitive inhibitor of GLUT1.  The 
graph shows the deterioration of the bistability specifically a slant towards the low 
concentrations of glucose.  This behavior could be explained that as glucose levels become lower 
the inhibitor prevents most glucose from entering the cell therefore extremely lowering glucose 
metabolism.  It appears as though the high flux state has been completely eliminated with this 
concentration of WZB117. 
    The next inhibitor displayed is AZD7545, a competitive inhibitor of PDK2.  The bistability is 
heavily affected by the addition of 0.06 mM of AZD7545.  Not only is the overall flux of 
glycolysis lowered but a slant also occurs with the graph slanting downward towards high lactate 
concentrations.  
     TEPP-46 is an activator of PKM2 and is shown in Figure 1 at 5 mM.  At this concentration 
the overall flux of glycolysis is increased, and the rate of lactate flux is increased as well.  This 
effect on its own does not accomplish lowering the lactate flux but could be useful if paired with 
an inhibitor to get to a high flux state which produces less lactate.  This combination is expanded 
upon in the combinations section below. 
     Palmitoyl-CoA is an inhibitor of PFK-1 and is shown at a concentration of 1mM in Figure 1.  
Its affects were similar to that of AZD7545 with a lower overall glycolysis flux as well as lower 
lactate flux. 
     Past research on the knock down of LDH has shown a lowering in the overall flux of glucose 
metabolism [17].  The competitive inhibitor FX11 did this, and at a concentration of 50mM it 
can be seen on Figure 1 that while bistability remains, the former high flux state has been cut 
nearly in half. In addition, the rate of lactate export is also reduced in a proportional manner. The 
impact of a range of FX11 concentrations can be seen below in Figure 2.  Again, an increase in 
the concentration of FX11 causes a lowering in glycolysis flux. The concentration of lactate is 





Figure 1 Displays inhibitors and the activator at different concentrations. Included is a negative control with no 
inhibitors or activators.  The plots shown are plotted with extracellular lactate vs extracellular glucose vs glycolysis 
flux.  
 
3.2 Effect of Inhibitors on Glucose Flux   
     In addition to testing at a constant inhibitor value with varying lactate and glucose, we also 
tested across a range of inhibitor values while holding lactate constant. This was done for a few 
of the inhibitors across their most sensitive concentrations.  The therapeutics shown this way are 





      
Figure 2 shows the graphs of different inhibitor concentrations for LDH inhibitor FX11, PFKFB inhibitor YZ9 and 
PKM2 inhibitor TEPP-46 
     In Figure 2 shows four concentrations of FX11 and its impact on glycolysis flux.  As the 
lactate inhibitor concentration is increased the overall flux goes down lowering the high flux 
state.  In addition, the unstable steady state appears to get steeper and this follows as the high 
flux state is approaching the low flux state.  This demonstrates the behavior of FX11 showing 
how it lowers the flux of glycolysis. 
     The behavior of PFKFB inhibitor is challenging to observe in 3 dimensions as its changes 
maintain the overall shape but seem to lengthen the unstable steady state.  Figure 2 shows this 
behavior across a range of concentrations. 
     The activation of PKM2 in Figure 2 shows an increase in the overall flux of the reaction with 
the low flux state moving up and the unstable steady state becoming narrower.  While PKM2 
activation may not be desirable on its own for lowering lactate flux, it is possible that this 






3.3 Combinations and Future Paths 
     After modeling all the selected inhibitors and activator on their own, a few combinations of 
therapeutics were tested.  In these combinations, we focused on not only lowering lactate flux 
but also trying to maintain a reasonably high glycolysis flux.  This would be ideal because then 
the cells would still be productive and would create less lactate. To achieve this balance of 
affects, we looked to TEPP-46 the PKM2 activator, and FX11 the LDH inhibitor.  After 
combining them at selected concentrations an outcome is shown in Figure 3. 
Figure 3 Displays the combination of 30 mM of FX11 and 10 mM of TEPP-46 along with a graph with no inhibitors 
or activators for comparison. 
     In Figure 3, there is a single steady state that occurs at around half the rate of the previous 
high glycolysis flux.  This state also produces less lactate, a desirable trait as previously 
explained.  The combinations of said therapeutics would be interesting to examine further 
possibly with an optimization to more precisely tune the concentrations for desirable behavior 
could be carried out on the new model, however this is beyond the scope of this research. 
     Overall this research was able to incorporate inhibitors and activators into a glucose 
metabolism model as to show their effects over different concentrations.  This model can be used 
for future use to find optimized concentrations of inhibitors and activators to produce the desired 
impact on CHO cells.  Even in this study in which the concentrations selected were not 
optimized, potent and promising effects were observed on the lowering of lactate flux and 
glycolysis flux by inhibitors and activators.  These therapeutics can be used in cell culture and in 
the study of cancer metabolism in the future and this model provides a toolbox to probe the 
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